The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).

Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.

Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.

Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.

Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.

Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.

AbbVie shared Phase 3 CANOVA trial results for the VenDex combo in treating relapsed or resistant multiple myeloma in patients with two or more prior treatments.

JCR Pharmaceuticals Co., Ltd. has disclosed critical findings from the midway 52-week data of its global research phase I/II involving JR-171 (lepunafusp alfa) in patients diagnosed with mucopolysaccharidosis type I.

Geron Corporation declared that the Marketing Authorization Application concerning imetelstat-a novel experimental telomerase inhibitor-has been accepted and validated by the EMA.

FDA accepts Priority Review of Odronextamab BLA for Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma.

IMUNON released preliminary PFS and OS statistics related to IMNN-001 from its Phase 1/2 OVATION 2 Investigation.

Structure Therapeutics has revealed encouraging results from its Phase 1b incremental dose study of its exclusive oral GLP-1 receptor agonist, GSBR-1290, in overweight or obese individuals.